Trelegy Ellipta - AU (Fluticasone furoate + umeclidinium bromide + vilanterol trifenatate Inhaler) 100mcg+62.5 mcg+25 mcg x30doses

Trelegy Ellipta is a triple-action inhaler combining fluticasone, umeclidinium, and vilanterol for long-term asthma and COPD maintenance. This once-daily inhaler delivers 100 mcg fluticasone + 62.5 mcg umeclidinium + 25 mcg vilanterol per dose in a 30-dose foil strip.

Strength

100mcg+62.5 mcg+25 mcg x30doses

Pack Size

Storage

Ambient

Manufacturer / TM Owner

GlaxoSmithKline AU

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trelegy Ellipta is used for daily maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in adults. It combines an inhaled corticosteroid (fluticasone) with a long-acting muscarinic antagonist (umeclidinium) and a long-acting beta2-adrenergic agonist (vilanterol) to help control symptoms and reduce flare-ups.

Side Effects

This inhaler helps open airways, reduce inflammation, and improve breathing over time. Users may notice fewer coughing episodes and less wheezing with regular use. Effects build gradually and are most noticeable when used consistently as prescribed.

Precautions & Warnings

Store the inhaler at room temperature away from moisture and heat. Keep the inhaler sealed in its foil pouch until ready to use. Rinse your mouth with water after each use to reduce the risk of oral infections. Avoid exposing the inhaler to extreme temperatures or direct sunlight.

Avoid Interactions

Caution is advised when using other inhaled medicines, especially long-acting beta agonists or anticholinergics. Certain heart medications and diuretics may increase the risk of side effects. Always inform your healthcare provider about all medications you are taking before starting this inhaler.

Frequently Asked Questions

Trelegy Ellipta is used for long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).

Each Trelegy Ellipta inhaler contains 30 doses, designed for once-daily use over one month.

No, Trelegy Ellipta is not a rescue inhaler and should not be used to treat sudden breathing attacks.

Store the inhaler at room temperature in a dry place, and keep the foil pouch sealed until use.

Common effects may include sore throat, headache, or cough. Rinse your mouth after use to reduce throat irritation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.